CHI Advisors’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

CHI Advisors’s Portfolio GTHX Stock Details GTHX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-333,945	Closed	-$1.81M	–	27
2022 Q4	$1.81M	Buy	333,945 +10,000	+3%	+$83.8K	0.48%	19
2022 Q3	$4.05M	Sell	323,945 -443,290	-58%	-$5.06M	1.09%	16
2022 Q2	$3.79M	Buy	767,235 +278,600	+57%	+$1.54M	1.45%	16
2022 Q1	$3.71M	Buy	488,635 +258,635	+112%	+$2.45M	1.58%	16
2021 Q4	$2.35M	Buy	230,000 +180,000	+360%	+$2.29M	0.78%	17
2021 Q3	$671K	Hold	50,000	–	–	0.2%	17
2021 Q2	$1.1M	Hold	50,000	–	–	0.26%	16
2021 Q1	$1.2M	Sell	50,000 -12,000	-19%	-$279K	0.24%	15
2020 Q4	$1.11M	Sell	62,000 -22,000	-26%	-$329K	0.31%	14
2020 Q3	$970K	Buy	84,000 +40,000	+91%	+$660K	0.35%	14
2020 Q2	$1.07M	Buy	+44,000	New	+$728K	0.42%	12

Other funds holding GTHX

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CHI Advisors's GTHX Position: Q1 2023 in Review

CHI Advisors sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q1 2023, closing a stake of 333,945 shares — an estimated $1.81M sold.

CHI Advisors first reported a position in GTHX in Q2 2020 and held it in 11 quarters. The position peaked at $4.05M in Q3 2022. 96 funds tracked by Wall St. Rank hold GTHX as of Q1 2023.

CHI Advisors reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
CHI Advisors sold 333,945 G1 Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $1.81M.
CHI Advisors first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2020 and held it in 11 quarters.
CHI Advisors's G1 Therapeutics, Inc. Common Stock position peaked at $4.05M in Q3 2022.
96 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q1 2023.

Based on CHI Advisors's 13F filing for Q1 2023, filed 11 May 2023.